dc.contributor | Universidade Estadual Paulista (UNESP) | |
dc.creator | Paiva, C. E. | |
dc.creator | Linde, Sandra Aparecida Drigo | |
dc.creator | Rosa, F. E. | |
dc.creator | Neto, F. A. Moraes | |
dc.creator | Caldeira, Jose R. F. | |
dc.creator | Soares, F. A. | |
dc.creator | Domingues, Maria Aparecida Custódio | |
dc.creator | Rogatto, Silvia Regina | |
dc.date | 2014-05-20T13:38:50Z | |
dc.date | 2016-10-25T16:54:53Z | |
dc.date | 2014-05-20T13:38:50Z | |
dc.date | 2016-10-25T16:54:53Z | |
dc.date | 2010-04-01 | |
dc.date.accessioned | 2017-04-05T20:36:04Z | |
dc.date.available | 2017-04-05T20:36:04Z | |
dc.identifier | Annals of Oncology. Oxford: Oxford Univ Press, v. 21, n. 4, p. 734-740, 2010. | |
dc.identifier | 0923-7534 | |
dc.identifier | http://hdl.handle.net/11449/13470 | |
dc.identifier | http://acervodigital.unesp.br/handle/11449/13470 | |
dc.identifier | 10.1093/annonc/mdp518 | |
dc.identifier | WOS:000276045600009 | |
dc.identifier | http://dx.doi.org/10.1093/annonc/mdp518 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/860791 | |
dc.description | Background: The clinical relevance of transforming growth factor-beta (TGF-beta)-signalling pathway in breast carcinomas (BCs) remained elusive. This study aimed to evaluate the prognostic value of TGF-beta and transforming growth factor-beta type II receptor (TGF-beta RII) expression levels in tumour cells and their association with the established biomarkers in BC.Patients and methods: In 324 BC from patients with long-term follow-up, the TGF-beta 1 and TGF-beta RII transcript and protein expression levels were assessed.Results: TGF-beta 1 and TGF-beta RII down-expression was significantly associated with BC. Negative TGF-beta 1 and TGF-beta RII protein status was associated with the development of distant metastasis (P = 0.003 and P = 0.029, respectively). In multivariate analysis, TGF-beta 1-positive tumours were associated with increased disease-free survival (DFS) [hazard ratio (HR) = 0.489, P = 0.003]. TGF-beta RII positivity was an independent prognostic factor for DFS (HR = 0.439, P = 0.001) and overall survival (OS) (HR = 0.409, P = 0.003) in human epidermal growth factor receptor2 (HER2)-negative patients. Absence of TGF-beta 1 and TGF-beta RII proteins in breast tumour cells was significantly associated with metastasis development.Conclusions: To the best of our knowledge, this is the first report indicating the relevance of HER2 status in discriminating TGF-beta RII as a prognostic marker for DFS and OS in human BC. These data indicate that TGF-beta RII protein analysis in tumour cells could be introduced in clinical practice as additional prognostic biomarker in HER2-negative BC. | |
dc.description | Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) | |
dc.description | Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) | |
dc.language | eng | |
dc.publisher | Oxford University Press | |
dc.relation | Annals of Oncology | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | breast cancer | |
dc.subject | HER2 | |
dc.subject | prognostic markers | |
dc.subject | TGF-beta 1 | |
dc.subject | TGF-beta RII | |
dc.title | Absence of transforming growth factor-beta type II receptor is associated with poorer prognosis in HER2-negative breast tumours | |
dc.type | Otro | |